Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.
Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.
“Dr. Stoddard is a foundational building block of the Novavax commercial team,” said John Trizzino, Senior Vice President, Commercial Operations. “His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
